Entry Detail



General Information

Database ID:exR0082588
RNA Name:TAGLN2
RNA Type:mRNA
Chromosome:chr1
Starnd:-
Coordinate:
Start Site(bp):159918107End Site(bp):159925732
External Links:ENSG00000158710



Disease Information

Disease Name:Fragile X Syndrome
Disease Category:Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:D005600
Type:Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA



Expression Detail

GEO ID:GSE83556
Description:Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:Disease vs Control
Case Disease Type:Fragile X Syndrome
Case Disease SubType:NA
Case Sample:Fragile X Syndrome
Control Sample:Normal
Number of Case:22
Number of Control:18
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC004922.1
chr7
99325879
99394653
+
AC010422.3
chr19
12643831
12648397
-
AC011462.1
chr19
41350853
41425001
+
AC090360.1
chr18
80034346
80097088
+
AC093525.2
chr16
2496032
2520218
+
ACADVL
chr17
7217125
7225266
+
ACTB
chr7
5527148
5563784
-
ACTG1
chr17
81509971
81523847
-
ACTR8
chr3
53867066
53882152
-
ADD3
chr10
109996368
110135565
+
ADIPOR2
chr12
1688574
1788674
+
ADPRHL2
chr1
36088892
36093932
+
ADRM1
chr20
62302093
62308862
+
AGK
chr7
141551278
141655244
+
AK4
chr1
65147549
65232145
+
AKIP1
chr11
8911139
8920084
+
AL035078.4
chr11
31812391
32104665
+
AL136454.1
chr1
192716132
192716653
+
AL590764.2
chrX
71103987
71111575
-
ALDOA
chr16
30064164
30070457
+
miRNA targets:
miRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa-miR-652-3p
chrX
110055389
110055409
+
hsa-miR-1294
chr5
154347153
154347174
+
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC007952.4
chr17
19112000
19112636
-
AC067852.2
chr17
42552436
42554748
-
AC132192.2
chr11
9459556
9460702
-
AL008721.2
chr22
25476218
25479971
+
AL022311.1
chr22
37876148
37895563
+
Display:



Experiment Detail

GEO ID:GSE83556
Sample Source:Amniotic Fluid
Source Fraction:Supernatant
Platform:GPL570
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:17063
Sample treatment protocol:RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).



Reference

PMID:NA
Title:NA
Author:NA
Journal:NA
Description:NA